Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391066 · ClinicalTrials.gov registry record · Phase 2
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 627
- Enrollment target
NCT00391066 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 627 participants.
The verdict
NCT00391066, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 627 participants
- Enrollment target
Study Summary
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.
Interventions
- DRUG FCR
- DRUG FCR + Lumiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00391066
The ClinicalTrials.gov registry entry for NCT00391066 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 627 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FCR is the first listed.
NCT00391066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00391066 about?
NCT00391066 is a clinical study titled "Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)". This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.
What is the current status of trial NCT00391066?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 627 participants. The study started on 2006-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00391066?
The interventions under investigation include: FCR (DRUG), FCR + Lumiliximab (DRUG).
Who is sponsoring clinical trial NCT00391066?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.